DNLI Valuation

Denali Therapeutics Inc

Add to Watchlist

Advanced Chart

13.670

-0.64(-4.472%)1D

Overview
Forecast
Valuation
Earnings

DNLI Relative Valuation

DNLI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNLI is overvalued; if below, it's undervalued.

Historical Valuation

Denali Therapeutics Inc (DNLI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 80.44 is considered Undervalued compared with the five-year average of -13.27. The fair price of Denali Therapeutics Inc (DNLI) is between 44.18 to 55.17 according to relative valuation methord. Compared to the current price of 13.67 USD , Denali Therapeutics Inc is Undervalued By 69.06%.

Relative Value

Fair Zone

44.18-55.17

Current Price：13.67

69.06%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.77

P/B

Median3y

2.92

Median5y

4.18

-18.49

FCF Yield

Median3y

-11.24

Median5y

-6.57

Competitors Valuation Multiple

The average P/S ratio for DNLI's competitors is 1056.65, providing a benchmark for relative valuation. Denali Therapeutics Inc Corp (DNLI) exhibits a P/S ratio of 81.34, which is -92.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DNLI.O

Denali Therapeutics Inc

81.34

Average P/S: 1056.65

1.99B